These do two different jobs. Aquagold delivers product into the skin; microneedling injures the skin so it rebuilds itself. Aquagold is a small stamp with a ring of hollow gold-plated microneedles, topped by a vial. Whatever is in the vial — commonly dilute botulinum toxin, hyaluronic acid, PRP or vitamins — is deposited into the superficial skin as the needles go in. It is a delivery device, not a collagen-induction treatment.
One fact readers should have plainly: Aquagold has no FDA 510(k) clearance. A search of the FDA device databases under that name returns no results. In June 2021 the FDA issued a warning letter to Aquavit Pharmaceuticals citing adulteration and misbranding, and stating that microneedling devices for aesthetic use are Class II devices requiring premarket notification, which the company had not submitted. Whether that has since been resolved could not be verified; as of the FDA data snapshot in July 2026, no 510(k) exists. This is a statement about regulatory status, not about whether anyone has been harmed.
Standard microneedling is on the opposite footing. SkinPen holds a De Novo authorisation (DEN160029, granted 1 March 2018) that created the microneedling device category, with a real cosmetic indication for facial acne scars. Dermapen 4 was cleared in December 2022 for facial acne scars in Fitzpatrick I–V.
Depth is the other honest contrast, and it is large. Standard microneedling pens work at up to 2.5 to 3.0 mm, deep in the dermis, which is where collagen remodelling happens. Aquagold works far shallower — though its exact needle length is not documented in any primary source.
Sometimes called a "microinfusion" or "microchannel" device. There is no motor and no energy source.
Also no energy source, but the needles are driven vertically at speed and to a set depth.
The needles create shallow openings and deposit the compounded solution as they pass. The result depends heavily on what was in the vial.
Thousands of vertical channels trigger the normal wound-healing cascade — platelet activity, growth factor release, fibroblast activation, new collagen and elastin remodelling. Nothing is added.
Needle count, gauge and depth are not documented in any FDA or manufacturer source we could verify. Clinic marketing commonly quotes 20 needles at 600 microns; treat that as an advertising claim, not a specification.
Both figures come from the devices' FDA summaries. SkinPen's pivotal study used a maximum needle length of 2.5 mm.
Whether that produces a lasting change depends entirely on the product, and no Aquagold-specific published trial could be located.
A 2024 network meta-analysis of 24 randomised trials and 1,546 participants found microneedling combined with another modality outperformed microneedling alone, with microneedling plus chemical peel ranking best.
The FDA's 2021 warning letter to the manufacturer stated that microneedling devices for aesthetic use are Class II devices under 21 CFR 878.4430 and require a 510(k), and that none had been submitted.
SkinPen via De Novo DEN160029 (2018) and K202243 (2021); Dermapen 4 via K221070 (2022), facial acne scars in Fitzpatrick I–V, with no neck indication.
Clinics describe brief flushing and pinpoint redness. No study measures it, and there is no labelled figure, so no duration is quoted here.
This is the conventional clinical description rather than a labelled figure.
Microneedling changes the skin's structure, slowly. The mechanism is well described: mechanical injury, healing cascade, new collagen. That is why it is a course of three to six sessions rather than a single appointment, and why the authorised claim is about the appearance of acne scars rather than about tightening or contour.
Aquagold changes what is in the skin, briefly. The device's value is the channel it opens for something else. That means the honest question is not "does Aquagold work" but "does the thing being delivered work, delivered this way, at this depth." The FDA's own warning letter listed the manufacturer's claims — micro-doses of a drug or biologic just under the dermis, acne scars, fine lines, hyperhidrosis, alopecia, collagen and elastin stimulation, wound healing — and concluded that on those claims the product is a device requiring clearance.
No Aquagold-specific published trial could be located. Whatever a clinic cites for it is almost certainly evidence about the ingredient, or about microneedling generally, not about this device.
One more thing worth knowing: the substances most often loaded into it, such as dilute botulinum toxin injected intradermally for a "glow" effect, are themselves off-label uses of those drugs. Off-label use is legal and routine, but it should be stated rather than implied.
A 2025 systematic review of granulomatous reactions after microneedling (Friedmann and colleagues, Dermatologic Surgery 51(3):263-6, PMID 39584690) collected 13 studies and 15 patients aged 26 to 74 with non-necrotising granulomatous inflammation after treatment. Motorised microneedling pens and topical vitamin C application were implicated in the majority of cases. Delayed-type hypersensitivity was the usual proposed mechanism, though patch testing was rarely done. Treatment outcomes were inconsistent — some cases resisted topical steroids, oral antibiotics and systemic anti-inflammatories.
Those were mostly mechanical microneedling cases, but the transferable lesson lands squarely on a delivery device. The implicated trigger was a substance applied into open microchannels. Aquagold's entire purpose is to put a substance into open microchannels. That does not mean it causes granulomas — no such case series exists for it — but it does mean the sterility, sourcing and composition of what goes in the vial is a fair thing to ask about, and that "just a vitamin cocktail" is not a reason to relax.
The same caution applies to anything applied after standard microneedling — serums, growth factors, exosome products — for exactly the same reason.
Tell your provider at booking if you get cold sores. Antiviral medication is started in advance, not after a blister appears. There is no published data on cold-sore reactivation after RF microneedling specifically; the practice is carried over from laser resurfacing, where it is well documented.